In HNSCC, where erlotinib and gefitinib have shown limited efficacy as monotherapies, afatinib has emerged as a promising drug due to its ability to inhibit the ErbB family and its encouraging preclinical and early clinical studies [85,87]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.